retatrutide nonalcoholic fatty liver disease nash trial Triple hormone receptor agonist for metabolic dysfunction-associated steatotic disease: a randomized phase 2a Fatty Liver Disease Clinical Trials

While bloating (often described as abdominal distension in clinical terms) is reported by patients, it is generally less commonly reported than nausea or diarrhoea

Look at the alternative: the PlexusDx Weight Management Protocols provide month-to-month tirzepatide in injection and oral formats, or take the Precision Peptide Genetic Test to read your metabolic pathway first

May maintain on 4-6mg weekly Lost weight on 8mg weekly

While the main substance patent for semaglutide is expected to expire in 2026, other patents, especially those covering specific formulations, uses, and delivery devices, may extend protections into the 2030s, effectively delaying generic entry

JCI Insight 6 , e153732 (2021)